Study ID: Novartis CFTY720D2405 TRANSITION

TRANSITION: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod


Fingolimod is a new type of medicine known as a sphingosine-1-phosphate (S1-P) receptor modulator. Fingolimod has been approved under the trade name GILENYA and is a prescription medicine given orally (by mouth) that treats multiple sclerosis (MS). Natalizumab is another drug that comes under the trade name of TYSABRI and is also given to treat MS. Patients and their physicians may have changed treatment from TYSABRI to GILENYA or have planned to change the treatment from TYSABRI to GILENYA. The main purpose of this study is to understand the safety of fingolimod in these patients. About 1500 patients will be enrolled in this study globally. Each patient will be followed for 2 years after the enrollment. This study will collect long-term safety information on patients treated with natalizumab within last 12 months and who have started on GILENYA for the treatment of MS, in order to monitor and further describe the safety of GILENYA.

Fargo Region
Principal Investigator:
Susan Scarberry


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list